A A

References

  1. National Breast Cancer Centre. Clinical practice guidelines for the management of advanced breast cancer. National Breast Cancer Centre, Camperdown, 2001.
  2. Kirsch DG and Loeffler JS. Brain metastases in patients with breast cancer: new horizons. Clin Breast Cancer. 2005;6(2):115-124.
  3. Lin NU, Bellon JR and Winer EP. CNS metastases in breast cancer. J Clin Oncol. 2004;22(17):3608-17.
  4. Arslan C, Dizdar O and Altundag K. Systemic treatment in breast-cancer patients with brain metastasis. Expert Opin Pharmacother. 2010;11(7):1089-100.
  5. Lin NU and Ramakrishna N. Management of brain metastases in breast cancer Up-to-date. 2012;19.3(January 2012).
  6. Kaal E, Taphoorn M and Vecht C. Symptomatic management and imaging of brain metastases. Journal of Neuro-Oncology 2005;75(1):15-20.
  7. Cancer Australia. Management of Central Nervous System (CNS) metastases in women with secondary breast cancer: a systematic review. Cancer Australia, Surry Hills NSW, 2013.
  8. National Health and Medical Research Council (NHMRC). NHMRC additional levels of evidence and grades for recommendations for developers of guidelines. NHMRC, Commonwealth of Australia, 2009.
  9. Hillier S, Grimmer-Somers K, Merlin T, et al. FORM: An Australian method for formulating and grading recommendations in evidence-based clinical guidelines. BMC Medical Research Methodology. 2011;11(23):11-23.
  10. National Breast and Ovarian Cancer Centre (NBOCC). Multidisciplinary care in Australia: a national demonstration project in breast cancer. NBOCC, Sydney, 2003.
  11. National Breast and Ovarian Cancer Centre (NBOCC). Multidisciplinary care principles for advanced disease: a guide for cancer health professionals. NBOCC, Surry Hills, NSW, 2008.
  12. Hart MG, Grant R, Walker M and Dickinson HO. Surgical resection and whole brain radiation therapy versus whole brain radiation therapy alone for single brain metastases. Cochrane Database of Systematic Reviews. 2011;Issue 4, Art. No: CD003292.
  13. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363(9422):1665-72.
  14. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006;295(21):2483-91.
  15. Akyurek S, Chang EL, Mahajan A, et al. Stereotactic radiosurgical treatment of cerebral metastases arising from breast cancer. Am J Clin Oncol. 2007;30(3):310-4.
  16. Kocher M, Soffietti R, Abacioglu U, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol. 2011;29(2):134-41.
  17. Soffietti R KM, Abacioglu UM, Villa S, Fauchon F, Baumert BG, Fariselli L, Tzuk-Shina T, Kortmann RD, Carrie C, Ben Hassel M, Kouri M, Valeinis E, van den Berge D, Mueller RP, Tridello G, Collette L, Bottomley A,. A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol. 2013;31(1):65-72.
  18. Mikkelsen T, Paleologos NA, Robinson PD, et al. The role of prophylactic anticonvulsants in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96(1):97-102.
  19. Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;54(10):1886-93.
  20. Vecht CJ, Hovestadt A, Verbiest HB, et al. Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology. 1994;44(4):675-80.
  21. Austroads. Assessing fitness to drive for commercial and private vehicle drivers: Medical standards for licensing and clinical management guideline. Austroads, 2012.
  22. Beran RG. Analysis of the latest Austroads guidelines for fitness to drive as promulgated in March 2012. Intern Med J. 2013;43(8):849-53.
  23. Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2012;30(4):419-25.
  24. Sperduto PW, Kased N, Roberge D, et al. Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int J Rad Oncol Biol Phys. 2012;82(5):2111-17.
  25. Harwood AR and Simson WJ. Radiation therapy of cerebral metastases: a randomized prospective clinical trial. Int J Radiat Oncol Biol Phys. 1977;2(11-12):1091-4.
  26. Kurtz JM, Gelber R, Brady LW, et al. The palliation of brain metastases in a favorable patient population: a randomized clinical trial by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1981;7(7):891-5.
  27. National Institute for Clinical Excellence (NICE). Supportive and palliative care: the Manual NICE, United Kingdom (UK), 2004.
  28. Mehta MP, Paleologos NA, Mikkelsen T, et al. The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96(1):71-83.
  29. Pestalozzi BC, Holmes E, de Azambuja E, et al. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). Lancet Oncol. 2013;14(3):244-8.
  30. Bartsch R, Rottenfusser A, Wenzel C, et al. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. J Neurooncol. 2007;85(3):311-7.
  31. Church DN, Modgil R, Guglani S, et al. Extended survival in women with brain metastases from HER2 overexpressing breast cancer. Am J Clin Oncol. 2008;31(3):250-4.
  32. Dawood S, Broglio K, Esteva FJ, et al. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol. 2008;19(7):1242-8.
  33. Park IH, Ro J, Lee KS, et al. Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer. Ann Oncol. 2009;20(1):56-62.
  34. Le Scodan R, Jouanneau L, Massard C, et al. Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death. BMC Cancer. 2011;11: 395.
  35. Lin NU, Dieras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 2009;15(4):1452-9.
  36. Bachelot T, Romieu G, Campone M, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013;14(1):64-71.
  37. Vecht CJ, Haaxma-Reiche H, van Putten WL, et al. Initial bolus of conventional versus high-dose dexamethasone in metastatic spinal cord compression. Neurology. 1989;39(9):1255-7.
  38. Sorensen S, Helweg-Larsen S, Mouridsen H and Hansen HH. Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. Eur J Cancer. 1994;30A(1):22-7.
  39. Heimdal K, Hirschberg H, Slettebo H, et al. High incidence of serious side effects of high-dose dexamethasone treatment in patients with epidural spinal cord compression. J Neurooncol. 1992;12(2):141-4.
  40. Patchell RA, Tibbs PA, Regine WF, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet. 2005;366(9486):643-8.
  41. Loblaw DA, Perry J, Chambers A and Laperriere NJ. Systematic review of the diagnosis and management of malignant extradural spinal cord compression: the Cancer Care Ontario Practice Guidelines Initiative's Neuro-Oncology Disease Site Group. J Clin Oncol. 2005;23(9):2028-37.
  42. Mintz AH, Kestle J, Rathbone MP, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer. 1996;78(7):1470-6.
  43. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322(8):494-500.
  44. Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol. 1993;33(6):583-90.
  45. Tsao MN, Lloyd N, Wong RKS, et al. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database of Systematic Reviews. 2012;Issue 4, Art No. CD003869.
  46. Kondziolka D, Patel A, Lunsford LD, et al. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys. 1999;45(2):427-34.
  47. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37(4):745-51.
  48. Rades D, Evers JN, Veninga T, et al. Shorter-course whole-brain radiotherapy for brain metastases in elderly patients. Int J Radiat Oncol Biol Phys. 2011;81(4):e469-73.
  49. Rades D, Haatanen T, Schild SE and Dunst J. Dose escalation beyond 30 grays in 10 fractions for patients with multiple brain metastases. Cancer. 2007;110(6):1345-50.
  50. Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009;10(11):1037-44.
  51. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA. 1998;280(17):1485-89.
  52. Yaneva MP and Semerdjieva MA. Assessment of the effect of palliative radiotherapy for cancer patients with intracranial metastases using EORTC-QOL-C30 questionnaire. Folia Med (Plovdiv). 2006;48(2):23-9.
  53. Rades D, Lohynska R, Veninga T, et al. Evaluation of 2 whole-brain radiotherapy schedules and prognostic factors for brain metastases in breast cancer patients. Cancer. 2007;110(11):2587-92.
  54. Priestman TJ, Dunn J, Brada M, et al. Final results of the Royal College of Radiologists' trial comparing two different radiotherapy schedules in the treatment of cerebral metastases. Clin Oncol (R Coll Radiol). 1996;8(5):308-15.
  55. Borgelt B, Gelber R, Kramer S, et al. The palliation of brain metastases: Final results of the first two studies by the Radiation Therapy Oncology Group. Int J Rad Oncol Biol Phys. 1980;6(1):1-9.
  56. Borgelt B, Gelber R, Larson M, et al. Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1981;7(12):1633-8.
  57. Wolstenholme V, Hawkins M, Ashley S, et al. HER2 significance and treatment outcomes after radiotherapy for brain metastases in breast cancer patients. Breast. 2008;17(6):661-5.
  58. Dawood S, Gonzalez-Angulo AM, Albarracin C, et al. Prognostic factors of survival in the trastuzumab era among women with breast cancer and brain metastases who receive whole brain radiotherapy: a single-institution review. Cancer. 2010;116(13):3084-92.
  59. Bazan F, Chaigneau L, Villanueva C, et al. Systemic high-dose intravenous methotrexate for central nervous system metastases in breast cancer. European Journal of Cancer. 2011;47(S348).
  60. Jacot W, Gerlotto-Borne MC, Thezenas S, et al. Carmustine and methotrexate in combination after whole brain radiation therapy in breast cancer patients presenting with brain metastases: a retrospective study. BMC Cancer. 2010;10:257.
  61. Ammirati M, Cobbs CS, Linskey ME, et al. The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96(1):85-96.
  62. Christodoulou C, Bafaloukos D, Linardou H, et al. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study. J Neurooncol. 2005;71(1):61-5.
  63. Freedman RA, Bullitt E, Sun L, et al. A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases. Clin Breast Cancer. 2011;11(6):376-83.
  64. Melisko ME, Anderson M, Scott J, et al. Phase II study of irinotecan and temozolomide in breast cancer patients with brain metastases or leptomeningeal disease that has progressed after stereotatic radiosurgery or whole brain radiation. ASCO Breast Cancer Symposium; 2009.
  65. Murphy C, Nulsen B, Rump M, et al. Phase II trial of patupilone in patients with breast cancer brain metastases progressing or recurring after whole brain radiotherapy. ASCO Breast Cancer Symposium 2009.
  66. Rivera E, Meyers C, Groves M, et al. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer. 2006;107(6):1348-54.
  67. Siena S, Crino L, Danova M, et al. Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. Ann Oncol. 2010;21(3):655-61.
  68. Metro G, Foglietta J, Russillo M, et al. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol. 2011;22(3):625-30.
  69. Lin NU, Eierman W, Greil R, et al. Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J Neurooncol. 2011;105(3):613-20.
  70. Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2008;26(12):1993-9.
  71. Husband DJ, Grant KA and Romaniuk CS. MRI in the diagnosis and treatment of suspected malignant spinal cord compression. Br J Radiol. 2001;74(877):15-23.
  72. Hagenau C, Grosh W, Currie M and Wiley RG. Comparison of spinal magnetic resonance imaging and myelography in cancer patients. J Clin Oncol. 1987;5(10):1663-9.
  73. Carmody RF, Yang PJ, Seeley GW, et al. Spinal cord compression due to metastatic disease: diagnosis with MR imaging versus myelography. Radiology. 1989;173(1):225-9.
  74. Li KC and Poon PY. Sensitivity and specificity of MRI in detecting malignant spinal cord compression and in distinguishing malignant from benign compression fractures of vertebrae. Magn Reson Imaging. 1988;6(5):547-56.
  75. Maranzano E and Latini P. Effectiveness of radiation therapy without surgery in metastatic spinal cord compression: final results from a prospective trial. Int J Radiat Oncol Biol Phys. 1995;32(4):959-67.
  76. Maranzano E, Latini P, Beneventi S, et al. Radiotherapy without steroids in selected metastatic spinal cord compression patients. A phase II trial. Am J Clin Oncol. 1996;19(2):179-83.
  77. Helweg-Larsen S. Clinical outcome in metastatic spinal cord compression. A prospective study of 153 patients. Acta Neurol Scand. 1996;94(4):269-75.
  78. Maranzano E, Latini P, Beneventi S, et al. Comparison of two different radiotherapy schedules for spinal cord compression in prostate cancer. Tumori. 1998;84(4):472-7.
  79. Greenberg HS, Kim JH and Posner JB. Epidural spinal cord compression from metastatic tumor: results with a new treatment protocol. Ann Neurol. 1980;8(4):361-6.
  80. Kovner F, Spigel S, Rider I, et al. Radiation therapy of metastatic spinal cord compression. Multidisciplinary team diagnosis and treatment. J Neurooncol. 1999;42(1):85-92.
  81. Ampil FL and Chin HW. Radiotherapy alone for extradural compression by spinal myeloma. Radiat Med. 1995;13(3):129-31.
  82. Rades D, Karstens JH and Alberti W. Role of radiotherapy in the treatment of motor dysfunction due to metastatic spinal cord compression: comparison of three different fractionation schedules. Int J Radiat Oncol Biol Phys. 2002;54(4):1160-4.
  83. Kased N, Binder DK, McDermott MW, et al. Gamma Knife radiosurgery for brain metastases from primary breast cancer. Int J Radiat Oncol Biol Phys. 2009;75(4):1132-40.
  84. Tsao MN, Rades D, Wirth A, et al. Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline. Practical Radiation Oncology. 2012;2(3):210-225.
  85. Kalkanis SN, Kondziolka D, Gaspar LE, et al. The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96(1):33-43.
  86. Rades D, Pluemer A, Veninga T, et al. Whole-brain radiotherapy versus stereotactic radiosurgery for patients in recursive partitioning analysis classes 1 and 2 with 1 to 3 brain metastases. Cancer. 2007;110(10):2285-92.
  87. Chatani M, Teshima T, Hata K, et al. Whole brain irradiation for metastases from lung carcinoma. A clinical investigation. Acta Radiol Oncol. 1985;24(4):311-4.
  88. Chatani M, Matayoshi Y, Masaki N and Inoue T. Radiation therapy for brain metastases from lung carcinoma. Prospective randomized trial according to the level of lactate dehydrogenase. Strahlenther Onkol. 1994;170(3):155-61.
  89. Murray KJ, Scott C, Greenberg HM, et al. A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104. Int J Radiat Oncol Biol Phys. 1997;39(3):571-4.
  90. DeAngelis LM, Currie VE, Kim JH, et al. The combined use of radiation therapy and lonidamine in the treatment of brain metastases. J Neurooncol. 1989;7(3):247-7.
  91. Eyre HJ, Ohlsen JD, Frank J, et al. Randomized trial of radiotherapy versus radiotherapy plus metronidazole for the treatment metastatic cancer to brain. A Southwest Oncology Group study. J Neurooncol. 1984;2(4):325-30.
  92. Komarnicky LT, Phillips TL, Martz K, et al. A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916). Int J Radiat Oncol Biol Phys. 1991;20(1):53-8.
  93. Mehta MP, Rodrigus P, Terhaard CH, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol. 2003;21(13):2529-36.
  94. Phillips TL, Scott CB, Leibel SA, et al. Results of a randomized comparison of radiotherapy and bromodeoxyuridine with radiotherapy alone for brain metastases: report of RTOG trial 89-05. Int J Radiat Oncol Biol Phys. 1995;33(2):339-48.
  95. Suh JH, Stea B, Nabid A, et al. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J Clin Oncol. 2006;24(1):106-14.
  96. Matsunaga S, Shuto T, Kawahara N, et al. Gamma Knife surgery for metastatic brain tumors from primary breast cancer: treatment indication based on number of tumors and breast cancer phenotype. J Neurosurg. 2010;113 Suppl 65-72.
  97. Iwamoto FM, Omuro AM, Raizer JJ, et al. A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol. 2008;87(1):85-90.
  98. Omuro AM, Raizer JJ, Demopoulos A, et al. Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial. J Neurooncol. 2006;78(3):277-80.
  99. Park YH, Park MJ, Ji SH, et al. Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer. 2009;100(6):894-900.
  100. Boccardo F, Kaufman B, Baselga J, et al. Evaluation of lapatinib (Lap) plus capecitabine (Cap) in patients with brain metastases (BM) from HER2+ breast cancer (BC) enrolled in the Lapatinib Expanded Access Program (LEAP) and French Authorisation Temporaire d'Utilisation (ATU) J Clin Oncol. 2008;26(Supplement 15):1094.
  101. Sutherland S, Ashley S, Miles D, et al. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience. Br J Cancer. 2010;102(6):995-1002.
  102. De Azambuja E, Lemort M, Rossari JR, et al. Phase I study of lapatinib and temozolomide combination for the treatment of progressive brain metastases in HER2-positive metastatic breast cancer patients (LAPTEM, LAP 111172). J Clin Oncol. 2011;29(Supplement 15):570.
  103. Lin N, Ramakrishna N, Younger WJ, et al. Phase I study of lapatinib in combination with whole-brain radiation therapy in patients with brain metastases from HER2-positive breast cancer. J Clin Oncol. 2010;28(Supplement 15):1154.
  104. Lin NU, Claus E, Sohl J, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008;113(10):2638-45.
  105. Addeo R, De Rosa C, Faiola V, et al. Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases. Cancer. 2008;113(9):2524-31.
  106. Cassier PA, Ray-Coquard I, Sunyach MP, et al. A phase 2 trial of whole-brain radiotherapy combined with intravenous chemotherapy in patients with brain metastases from breast cancer. Cancer. 2008;113(9):2532-8.
  107. Elaimy AL, Mackay AR, Lamoreaux WT, et al. Multimodality treatment of brain metastases: an institutional survival analysis of 275 patients. World J Surg Oncol. 2011;9:69.
  108. Ogawa K, Yoshii Y, Nishimaki T, et al. Treatment and prognosis of brain metastases from breast cancer. J Neurooncol. 2008;86(2):231-8.
  109. Rades D, Kueter JD, Gliemroth J, et al. Resection plus whole-brain irradiation versus resection plus whole-brain irradiation plus boost for the treatment of single brain metastasis. Strahlenther Onkol. 2012;188(2):143-7.
  110. Niwinska A, Tacikowska M and Murawska M. The effect of early detection of occult brain metastases in HER2-positive breast cancer patients on survival and cause of death. Int J Radiat Oncol Biol Phys. 2010;77(4):1134-9.
  111. Tancioni F, Navarria P, Mancosu P, et al. Surgery followed by radiotherapy for the treatment of metastatic epidural spinal cord compression from breast cancer. Spine (Phila Pa 1976). 2011;36(20):E1352-9.
  112. Talcott JA, Stomper PC, Drislane FW, et al. Assessing suspected spinal cord compression: a multidisciplinary outcomes analysis of 342 episodes. Support Care Cancer. 1999;7(1):31-8.
  113. Husband DJ. Malignant spinal cord compression: prospective study of delays in referral and treatment. BMJ. 1998;317(7150):18-21.
  114. Williams MP, Cherryman GR and Husband JE. Magnetic resonance imaging in suspected metastatic spinal cord compression. Clin Radiol. 1989;40(3):286-290.
  115. Hoskin PJ. Radiotherapy in symptom management.  In Doyle D, Hanks GW, MacDonald N (Eds) Oxford textbook of palliative medicine. Oxford University Press, United Kingdom (UK), 1993.
  116. Cairncross JG and MacDonald DR. Central nervous system emergencies. In Wittes RE, ed. Manual of oncologic therapeutics. JB Lippincott Company, USA, 1992.
  117. Coleman RE, Bertelli G, Beaumont T, et al. UK guidance document: treatment of metastatic breast cancer. Clin Oncol (R Coll Radiol). 2012;24(3):169-76.
  118. Watts K, Meiser B, Conlon H, et al. A specialist breast care nurse role for women with metastatic breast cancer: enhancing supportive care. Oncol Nurs Forum. 2011;38(6):627-31.
  119. Cheville A. Rehabilitation of patients with advanced cancer. Cancer. 2001;92(S4):1039-1048.
  120. Hoefnagel LD, van de Vijver MJ, van Slooten HJ, et al. Receptor conversion in distant breast cancer metastases. Breast Cancer Res. 2010;12(5):R75.
  121. Amir E, Clemons M, Purdie CA, et al. Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat Rev. 2012;38(6):708-14.
  122. Kaal EC and Vecht CJ. The management of brain edema in brain tumors. Curr Opin Oncol. 2004;16(6):593-600.
  123. Ryken TC, McDermott M, Robinson PD, et al. The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96(1):103-14.
  124. Cancer Council NSW. Understanding Brain Tumours: A guide for people with brain or spinal cord tumours, and their families and friends. Cancer Council NSW, Sydney, NSW, 2011.
  125. Ghods AJ, Munoz L and Byrne R. Surgical treatment of cerebellar metastases. Surg Neurol Int. 2011;2(6):159.
  126. Nguyen TT, Smith MV, Rodziewicz GS and Lemke SM. Hydrocephalus caused by metastatic brain lesions: treatment by third ventriculostomy. J Neurosurg Psychiatry. 1999;67(4):549-59.
  127. National Comprehensive Cancer Center (NCCN). NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers NCCN, Version 2, 2012.
  128. National Institute for Clinical Excellence (NICE). Advanced breast cancer: diagnosis and treatment. NICE, United Kingdom, 2009.
  129. Cardoso F, Fallowfield L, Costa A, et al. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22(Supplement 6):vi25-vi30.
  130. Soffietti R, Cornu P, Delattre JY, et al. Brain metastases: EFNS guidelines on brain metastases European Handbook of Neurological Management: Volume 1, 2nd Edition. 2011;1(2nd edition):437-445.
  131. Beslija S, Bonneterre J, Burstein HJ, et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol. 2009;20(11):1771-85.
  132. Feyer P, Sautter-Bihl ML, Budach W, et al. DEGRO Practical Guidelines for palliative radiotherapy of breast cancer patients: brain metastases and leptomeningeal carcinomatosis. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft 2010;186(2):63-69.
  133. Clinicaltrials.gov. Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer. http://clinicaltrials.gov/show/NCT01622868. Accessed: July 2013.
  134. Clinicaltrials.gov. Radiation Therapy With or Without Temozolomide in Treating Women With Brain Metastases and Breast Cancer. http://clinicaltrials.gov/show/NCT00875355. Accessed: July 2013.
  135. Clinicaltrials.gov. BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain. http://clinicaltrials.gov/show/NCT00397501. Accessed: July 2013.
  136. Clinicaltrials.gov. XERAD: A Study of Xeloda (Capecitabine) Plus Radiotherapy in Patients With Breast Cancer With Newly Diagnosed Brain Metastases http://clinicaltrials.gov/ct2/show/NCT00977379. Accessed: July 2013.
  137. Clinicaltrials.gov. GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases (GRABM-B). http://clinicaltrials.gov/ct2/show/NCT01480583. Accessed: July 2013.
  138. Clinicaltrials.gov. HKI-272 for HER2-Positive Breast Cancer and Brain Metastases. http://clinicaltrials.gov/show/NCT01494662. Accessed: July 2013.
  139. Clinicaltrials.gov. Radiation Therapy to the Head in Preventing Brain Metastases in Women Receiving Trastuzumab and Chemotherapy for Metastatic or Locally Advanced Breast Cancer. http://clinicaltrials.gov/show/NCT00639366. Accessed: July 2013.
  140. Clinicaltrials.gov. Stereotactic Radiosurgery or Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases That Have Been Removed By Surgery. http://clinicaltrials.gov/show/NCT01372774. Accessed: July 2013.
  141. Radiation Therapy Oncology Group (RTOG). A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases--RTOG CCOP Study. http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0933. Accessed: July 2013.
  142. Clinicaltrials.gov. Phase I Trial of Stereotactic Radiosurgery Following Surgical Resection of Brain Metastases http://www.cancer.gov/clinicaltrials/search/view?cdrid=706319&version=HealthProfessional. Accessed: February 2014.